We have said all along that we look at our investment in Gene Biotherapeutics as if we were investing in a private company. Since we plan on holding our shares for at least another 3-5 years, we don't care about there not being a market for the stock. Why should we care about a lack of liquidity when we have no intention of selling any of our shares for a long time.
Actually, we see this as an advantage, in the sense that it forces us to hang on to our shares, and not be influenced by prevailing market forces. If we were not distracted and didn't get caught up in all of the noise surrounding CELH, we would still likely have the 568,250 shares that we held in our Roth IRA account at an average price of $0.22.
Those shares today would be worth over $74 million
We have confidence that Chris Reinhard will get a deal done to fund a successful Phase 3 clinical trial. The filings are secondary to us. While it may be difficult now, we believe that things will ultimately improve.
Don't underestimate the importance of patience when investing in micro-caps.
News 
Market Data 
Discover 
AI
